Division of Immunology and Rheumatology, Stanford University, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA.
Division of Rheumatology, Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA, 8750 Wilshire Boulevard Suite 350, Beverly Hills, CA 90211.
Rheum Dis Clin North Am. 2021 Aug;47(3):481-499. doi: 10.1016/j.rdc.2021.04.010. Epub 2021 Jun 16.
Despite progress in the treatment of systemic lupus erythematosus (SLE), remission rates and health-related quality of life remain disappointingly low. The paucity of successful SLE clinical trials reminds us that we still have a long way to go. Nevertheless, there are clear signs of hope. We highlight results from recent studies of novel therapeutic strategies based on emerging insights into our understanding of SLE disease mechanisms. We also highlight several studies that inform optimal use of existing treatments to improve efficacy and/or limit toxicity. These developments suggest we may yet unlock the key toward more satisfactory treatment outcomes in SLE.
尽管系统性红斑狼疮（SLE）的治疗取得了进展，但缓解率和与健康相关的生活质量仍然低得令人失望。SLE 临床试验成功率低提醒我们，我们还有很长的路要走。然而，有明显的希望迹象。我们强调了基于对 SLE 疾病机制理解的新出现的见解的新型治疗策略的最新研究结果。我们还强调了几项研究，这些研究为优化现有治疗方法的使用提供了信息，以提高疗效和/或降低毒性。这些进展表明，我们可能还有望找到治疗 SLE 的更满意结果的关键。
